PLOS One has retracted five papers by Hoau-Yan Wang from the City University of New York and colleagues, according to Retraction Watch.
In the retraction notices, PLOS One says concerns had been raised about some figures in the papers. For instance, for one paper, the journal says there were irregularities in different panels of a figure, one panel lacked a positive control sample, and another appeared to be duplicated. The notice adds that while the corresponding author said that panel was inadvertently duplicated and provided a replacement, the other supporting data and comments did not appease its other concerns. The different notices add that Wang did not agree with the retractions.
Retraction Watch adds that other papers from Wang have also been subject to examination by PubPeer and by Elisabeth Bik, and two Alzheimer's disease-related papers have received expressions of concern.
It adds that Cassava Sciences has relied on work by Wang in its regulatory filings for its Alzheimer's disease drug simufilam. The Wall Street Journal reported in November that the US Securities and Exchange Commission is investigating whether Cassava included manipulated images in its regulatory filings. Retraction Watch noted previously that some of these concerns were raised by short-sellers in a citizen's petition to FDA to halt the company's trials. It now notes the agency denied that petition, saying it was not the appropriate venue for a complaint, as FierceBiotech reported in February.